QGEN Qiagen N.V.

All QGEN filings Filing statistics SEC

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Company profile

Ticker

QGEN

Exchange

NYSE

Website

www.qiagen.com

CEO

Peer Michael Schatz

Incorporated in

Netherlands

Location

Netherlands

Fiscal year end

Dec 31

Sector

Health Technology > Medical Specialties

Industry (SEC)

Biological Products, (No Diagnostic Substances)

Amgen • Gilead Sciences • Biogen • Moderna • Acorda Therapeutics • Bio-Techne • PDL BioPharma • BioNTech SE • Denali Therapeutics • Seattle Genetics ...

SEC CIK

0001015820

Corporate docs

Articles of Incorporation & Bylaws

QGEN stock data

S&P 500

1M 1Y 2Y 5Y

Company financial data Financial data

Chart QGEN financial data

Annual (USD)	Dec 18	Dec 17	Dec 16	Dec 15
Revenue	1.5B	1.42B	1.34B	1.28B
Net income	190.38M	40.39M	80.4M	130.15M
Diluted EPS	0.82	0.17	0.34	0.55
Net profit margin	12.68%	2.85%	6.01%	10.16%
Operating income	266.58M	153.42M	98.83M	179.5M
Net change in cash	68.49M	1.98M	-80.03M	-43.19M
Cash on hand	208.08M	139.6M	137.62M	217.64M
Cost of revenue	500.89M	494.98M	493.34M	454.33M

Financial data from Qiagen earnings reports

Institutional ownership Q3 2019

QGEN institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	254	268	-5.2%
Opened positions	29	38	-23.7%
Closed positions	43	40	+7.5%
Increased positions	99	100	-1.0%
Reduced positions	84	88	-4.5%

13F shares	Current	Prev Q	Change
Total value	8.05B	9.15B	-12.1%
Total shares	394.08M	372.09M	+5.9%
Total puts	138.05K	120.14K	+14.9%
Total calls	665.53K	243.19K	+173.7%
Total put/call ratio	0.2	0.5	-58.0%

Largest owners	Shares	Value	Change
RY Royal Bank of Canada	35.41M	$36.86M	-9.2%
Amundi Pioneer Asset Management	31.84M	$111.18M	+2.8%
Polar Asset Management Partners	30M	$34.69M	NEW
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	28.94M	$106.38M	+32.1%
Lombard Odier Asset Management	25.8M	$26.83M	0.0%
PUK Prudential	21.35M	$26.6M	+10.3%
Primecap Management	14.98M	$493.87M	-2.0%
CQS Cayman	13.2M	$13.71M	+6.5%
Massachusetts Financial Services	12.53M	$412.96M	+3.9%
Oaktree Capital Management	11.6M	$12.04M	-1.7%

Largest transactions	Shares	Bought/sold	Change
Polar Asset Management Partners	30M	+30M	NEW
Davidson Kempner Capital Management	0	-20M	EXIT
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	28.94M	+7.03M	+32.1%
PLRRF Polar Capital	1.2M	-6M	-83.3%
BCS Barclays	7.11M	+5.59M	+368.9%
RY Royal Bank of Canada	35.41M	-3.6M	-9.2%
JEF Jefferies	3.68M	+2.25M	+157.2%
C Citigroup	4.43M	+2.16M	+95.4%
PUK Prudential	21.35M	+2M	+10.3%
Alliancebernstein	2.73M	+1.95M	+249.3%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Guided Therapeutics • Ngen • Cepheid • Biocept • Third Wave • China Medical • Rosetta Genomics • WaferGen Bio-systems • NanoString • Metastat

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AACR, Academy, alpelisib, anonymized, antimicrobial, anytime, ARESdb, ASH, Barcelona, BIOSCIENCE, Boehringer, Brexit, cardiovascular, carrier, chemotherapy, circumstance, clean, compensatory, consortia, constrained, contemporary, correct, customizable, cybersecurity, cystic, de, depict, disaggregate, disaggregation, disregarded, divergent, diversified, Diversifying, DNeasy, Earth, editing, Ellume, epidermal, expedient, FastSelect, feed, Fidelio, formula, Formulatrix, fraudulent, fungal, GBS, gonorrhoeae, Hamilton, healthy, hereof, Hodgkin, hormone, immature, immunotherapy, Ingelheim, Interbank, interface, invoice, invoiced, invoicing, IVDR, Leipzig, LIAISON, London, LungCancer, MDAX, MetaSUB, Migration, Minden, myeloma, Natera, NeuMoDx, Nevada, Nonemployee, novo, orderly, PACT, perpetual, Pfizer, posed, possession, Postbank, postmarket, PowerSoil, predetermined, ProstateCancerPanel, push, quicker, ramp, Reaping, reinforcing, reorganization, repetitive, SRL, straddle, stranded, synchronized, syndromic, tailored, TMB, tradable, UCP, ultrasensitive, UMI, unbilled, unclear, upfront, upward, vendor, VIE, whichever, won

Removed: Abbott, adjunctive, AdnaGen, attractive, branch, BreastCancer, broaden, broker, called, cancelled, Carlsbad, cell, certifying, client, collectability, compact, consigned, consignment, consumption, curated, deliverable, demanding, digit, discontinuation, displacing, downstream, earliest, easy, EMD, emergency, equivocal, era, escrow, ESEQuant, expertly, expression, feedback, FIFO, Fisher, foregoing, Franklin, glucose, greatly, Grundstuecksverwaltungsgesellschaft, guaranteed, headcount, headwind, Hong, house, includable, Ingenuity, Inhibitor, IPO, Kong, Korean, LDT, lengthy, liquidated, livestock, loaned, Malaysia, Marseille, mbH, Merck, Millipore, Modaplex, neglect, older, optical, Pap, partly, perjury, persuasive, petition, plate, portable, preacquisition, Promega, pure, pursuing, QIAgility, QIAxcel, ratably, reagent, recover, relapse, remote, risky, Roche, roll, sharply, side, standardize, subdivision, succeed, surpassing, surtax, synergistic, Taiwan, tapping, tariff, Thermo, tube, twenty, unconsolidated, undisclosed, unprecedented, unsubordinated, urge, variant, visualizing, VSOE, warehouse, water

From filing 20-F 2018 FY